Chen Keyao, Toksoz Ahmet, Henchy Colin, Knapp Jessica, Lu Jie, Ranganathan Sarangarajan, Wang Huabo, Prochownik Edward V
Division of Hematology/Oncology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA 15224, USA.
School of Medicine, Tsinghua Medicine, Tsinghua University, Beijing 100084, China.
Cancers (Basel). 2025 Sep 14;17(18):3002. doi: 10.3390/cancers17183002.
: Hepatoblastoma (HB), the most common pediatric liver cancer, often bears mutations in and/or otherwise deregulates the oncogenic transcription factors β-catenin (B), YAP (Y) and NRF2 (N). HB research is hampered by a paucity of established cell lines, particularly those possessing these molecular drivers. All combinations of B, Y and N (BY, BN, YN and BYN) are tumorigenic when overexpressed in murine livers, but it has not been possible to establish cell lines from primary tumors. Recently, we found that concurrent, in vivo Crispr-mediated targeting of the tumor suppressor locus allows for immortalized cell lines to be efficiently generated. : We derived and characterized five immortalized cell lines from -targeted BN and YN HBs. Four of the above five cell lines retained their ability to grow as subcutaneous or "pseudo-metastatic" pulmonary tumors in the immunocompetent mice from which they originated. Most notably, when maintained under hypoxic conditions for as little as 2 days, BN cells transiently upregulated the expression of numerous endothelial cell (EC)-specific genes and acquired EC-like properties that benefited tumor growth. These lines and those from previously derived BY and BYN HBs also possessed similar sensitivities to four commonly employed chemotherapeutic drugs. : The above-described approach is currently the only means to generate HB cell lines with pre-selected and clinically relevant oncogenic drivers. Its generic nature should also allow bespoke HB cell lines with other oncogenic drivers to be readily produced. A collection of such cell lines will be useful for studying tumor cell-to-EC trans-differentiation, interactions with the immune environment and drug sensitivities.
肝母细胞瘤(HB)是最常见的儿童肝癌,常携带致癌转录因子β-连环蛋白(B)、Yes相关蛋白(Y)和核因子E2相关因子2(N)的突变和/或存在其他失调情况。HB的研究因缺乏成熟的细胞系而受阻,尤其是那些具有这些分子驱动因素的细胞系。当B、Y和N的所有组合(BY、BN、YN和BYN)在小鼠肝脏中过表达时都具有致瘤性,但无法从原发性肿瘤中建立细胞系。最近,我们发现,通过体内同时利用CRISPR介导靶向肿瘤抑制基因座能够高效生成永生化细胞系。:我们从靶向BN和YN的HB中获得并鉴定了五种永生化细胞系。上述五个细胞系中的四个保留了在其起源的免疫活性小鼠中作为皮下或“假转移性”肺部肿瘤生长的能力。最值得注意的是,当在低氧条件下维持仅2天时,BN细胞会短暂上调许多内皮细胞(EC)特异性基因的表达,并获得有利于肿瘤生长的EC样特性。这些细胞系以及先前获得的BY和BYN HB细胞系对四种常用化疗药物也具有相似的敏感性。:上述方法是目前生成具有预先选择的、临床相关致癌驱动因素的HB细胞系的唯一手段。其通用性还应允许轻松生产具有其他致癌驱动因素的定制HB细胞系。这样一组细胞系将有助于研究肿瘤细胞向内皮细胞的转分化、与免疫环境的相互作用以及药物敏感性。